key: cord-0925942-4gbdiosv authors: Núñez-Velasco, Santiago; Mercado-Pimentel, Rodrigo; Rodríguez-Arias, Regina title: Letter to the editor: Awake Craniotomy for Intracranial Gliomas during COVID-19 Pandemic date: 2020-05-30 journal: World Neurosurg DOI: 10.1016/j.wneu.2020.05.219 sha: f44d68852673ba4049a44f7fba2d4eb743ee3717 doc_id: 925942 cord_uid: 4gbdiosv nan Awake craniotomy technique is the gold standard to achieve maximum safe resection in patients with intracranial gliomas. However, in times of COVID-19, this technique is considered of high risk since it involves the management of the airway on more than one occasion (in the case of the sleep-awake-sleep technique), a very close and direct contact with the neuropsychologist during the stimulation and a lot of technical personnel and hardware within the operating room (monitoring equipment, navigation). 1,2,3 The initial response to the SARS-Cov-2 pandemic of most neurosurgical centers around the world was to defer elective surgeries and classify emergencies, postponing surgical treatment in a large group of patients. Glioma patients who are candidates for awake craniotomy could be included in this deferred group (mainly low-grade), since they maintain a high functional scale and do not present acute life-threatening neurological deterioration. However, we see a scenario in which even in reopening programs, biosafety precautions must be maintained since the risk of contagion continues and will remain latent, so strategies to offer patients this useful technique in a safe way should be implemented. 4, 5 Candidate patients for awake surgery are in two scenarios according to the WHO grade (low and high) of their tumor. The treatment consensus in the COVID-19 era for those with high-grade gliomas, is to perform the surgery as soon as possible (preferably within two weeks). While that in low-grade patients, more expectant behavior has been recommended, however, in this group of patients, early surgical treatment is essential to achieve supratotal resections that will impact the patient's disease-free period; so deferring their surgery further could lead to an increase in the functional deficit and cease to be good candidates for direct brain mapping. Therefore, we believe that regardless of the degree of injury, candidate patients should initiate a testing and isolation program to carry out their treatment as soon as possible. 4 The neurosurgical oncology teams will mainly face five types of patients: the non-COVID-19 patient, the asymptomatic carriers, the ones in the preclinical phase, the mild symptomatic, and the severe symptomatic. The first three types mentioned will be presented initially, without symptoms, so it is essential to implement detection strategies to ensure that the patient going to surgery is a patient without COVID-19. 6, 7, 8 Testing and isolation is the key to the selection in this COVID-19 pandemic; all patients who meet the conventional criteria for awake surgery must undergo to an epidemiological and clinical questionnaire, and RT-PCR test for SARS-CoV-2. If the test is negative, the patient must remain isolated for 14 days at home. During this quarantine, anesthetic and neuropsychological evaluations must be carried out by telemedicine, and daily monitoring of the neurological state to detect the early deterioration and verification of quarantine compliance must be done. Once the isolation period has been completed, the patient must return to the hospital. Upon admission, these patients will undergo to CT scan and a serum total antibody SARS-CoV-2 test (if the serum test is not available, a new PCR test must be done), by doing this clinical, radiological, molecular and serological all the screening recommendations are carried out. 5, 9, 10 The period of isolation allows us to rule out any preclinical patient (average five days) who has come out negative to RT-PCR, and the antibody testing 14 days later, added to the prior RT-PCR, allows us to achieve the maximum reported diagnostic sensitivity to have greater certainty that the patients that will undergo to awake mapping are a non-COVID-19 patients. 9, 11, 12 (Figure) ¿Awake craniotomy in SARS-CoV-2 positive patients? Numerous problems can occur when performing this technique in patients with COVID-19; some reports suggest that when patients are taken to surgery, positive for SARS-CoV-2 has the worst outcome. 13 Also, if the sleep-awake-sleep technique is used, active management of the airway is required on two occasions, one of them while the entire team is in the operating room. Other anesthetic techniques that could prevent this have been described, such as full awake technique. 15,16 However, in these cases, there is even a minimal risk of failure, being necessary to transform it into general anesthesia. 17 On the other hand, there is always the risk of seizures associated with electrical mapping, so the patient may lose control, generating secretions and, therefore, aerosols. 16 Finally, it is required within specialized hardware as well as the technical personnel who operate it; also the neuropsychologist is usually close to the patient, coordinating the application of the functional tasks and the interpretation of the same and even if the maneuvers were being performed remotely through a streaming transmission, patients might experience anxiety. 1,18 Psychological assistance in these cases is vital. Even in the scenario of community circulation of SARS-CoV-2, those patients with intracranial gliomas who meet the criteria for awake craniotomy should be operated with this technique as long as the presence of COVID-19 disease has been ruled out by various validated methods. Awake glioma surgery: technical evolution and nuances Precautions for Operating Room Team Members during the COVID-19 Pandemic Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures in a large tertiary hospital in Singapore Inpatient and outpatient case prioritization for patients with neuro-oncologic disease amid the COVID-19 pandemic: general guidance for neuro-oncology practitioners from the AANS/CNS Tumor Section and Society for Neuro-Oncology Surgical Management of Brain Tumor Patients in the COVID-19 Era Clinical features of patients infected with 2019 novel coronavirus in Wuhan Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility The Risk of COVID-19 Infection During Neurosurgical Procedures: A Review of Severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2) Modes of Transmission and Proposed Neurosurgery-Specific Measures for Mitigation Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus-2 Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection Neuroanesthesia Practice During the COVID-19 Pandemic Craniotomy under Local Anesthesia and Monitored Conscious Sedation for the Resection of Anesthetic Approach to High-Risk Patients and Prolonged Awake Craniotomy Using Dexmedetomidine and Scalp Block Risk factors for intraoperative stimulation-related seizures during awake surgery: an analysis of 109 consecutive patients Patient response to awake craniotomy -A summary overview The authors report no conflict of interest regarding the materials or methods used in this study or the findings specified in this paper. Author contributions to the study and manuscript preparation include all authors.Patient with indication and criteria for awake craniotomy Figure. -Testing and evaluation process to rule out COVID-19 in a patient awake craniotomy candidate. * In case of not having serum antibody tests, repeat RT-PCR.